Cycle Time Reduction Remains Elusive

August 25, 2015
Applied Clinical Trials Editorial Staff

Applied Clinical Trials

KMR Group reports that the duration of clinical trials continues to hold steady or increase despite ongoing efforts by biopharmaceutical companies to reduce cycle times.

KMR Group reports that the duration of clinical trials continues to hold steady or increase despite ongoing efforts by biopharmaceutical companies to reduce cycle times. KMR Group assessed cycle time trends for more than 6,000 Phase II/III clinical trials using proprietary industry data across 27 companies going back to 2005. The analysis focused on clinical trials across all therapeutic areas. KMR defines total cycle time as the interval from Protocol Approval to Clinical Trial Report (PA-CTR). The analysis reveals that both Phase II and III trials have increased significantly over the last 10 years and continue to rise. Phase III trials took a median 35.7 months for industry in 2005-07 and takes 42.9 months in 2012-14. 

 

Read the full release here.

Related Content:

News